Search
Histidine
go.drugbank.com/drugs/DB00117ApprovedInvestigationalNutraceuticalAn essential amino acid that is required for the production of histamine.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Elbasvir
go.drugbank.com/drugs/DB11574ApprovedElbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseDexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approvedCommonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions. … [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions.
Pyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedIt is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis
Mefloquine
go.drugbank.com/drugs/DB00358ApprovedIt was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976.
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications
Ammonia N-13
go.drugbank.com/drugs/DB09326ApprovedAmmonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease
Reviparin
go.drugbank.com/drugs/DB09259Approved[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.